Testing CT-95 in advanced cancers with mesothelin
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that shows a protein called mesothelin (your doctor can check this).
- You are well enough to be up and about (fully active or able to do light work).
- Your cancer can be measured with scans (like CT or MRI).
- Your organs (like liver, kidneys, bone marrow) are working well.
- You have not had a prior treatment that targets mesothelin (like CAR-T cells or a CD3-based drug).
- You are not currently in another experimental drug trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a lab-made immune therapy (anti-mesothelin CAR-T) for adults with solid tumors that have come back or did not respond to standard treatment. It targets cancers that are mesothelin-positive in tumor testing and aims to see if the treatment is safe and can work.
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
This trial tests a new drug called SY001, which targets a protein called mesothelin found on some cancer cells. It is designed for people with advanced ovarian or pancreatic cancer who have already tried other treatments and whose tumor tissue has mesothelin.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.